- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica or the Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 Amendment should benefit both parties from a cost...
“ Reports YCANTH® revenue of $3.2M for first quarter of 2024 “ “ Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans “ “...
WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica or the Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica or the Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Announces that YCANTH Receives New Chemical Entity Status
Verrica Pharma Reports Fourth Quarter and Full-Year 2023 Financial Results
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (œVerrica or œthe Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...